Back

Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma

Li, B.;Yang, J.;Cai, M.;Yee, S.;Carlson, D.;Smoot, R.;Baker, D.;Ilyas, S.

2026-06-25 Cancer Biology
10.64898/2026.06.24.734341 bioRxiv
Show abstract

Cholangiocarcinoma (CCA) is a lethal biliary cancer in which chemoresistance is nearly universal, and its tumor immune microenvironment is dominated by immunosuppressive tumor-associated macrophages (TAMs) that exclude cytotoxic CD8+ T cells. How tumor cells sustain this immunosuppressive state during chemotherapy is undefined. Here we demonstrate that therapy-induced senescent-like (Sen-L) cancer cells accumulate after gemcitabine/cisplatin in human and murine CCA, are predominantly cancer cells, and predict shorter survival. Genetic elimination of Sen-L cancer cells reduces tumor burden, lowers TAM abundance, and restores intratumoral CD8+ T cells, establishing them as causal drivers. Growth differentiation factor 15 (GDF-15) is the dominant Sen-L-secreted factor and reprograms macrophages to suppress CD8+ T cells through the non-canonical receptor TGFBR2 and STAT6, and p16-restricted Gdf15 silencing phenocopies Sen-L elimination. Combined with chemotherapy, Sen-L elimination improves survival beyond chemotherapy alone. These findings establish Sen-L cancer cells and their GDF-15 output as causal, targetable drivers of macrophage-mediated immune evasion in CCA. SIGNIFICANCE STATEMENTTherapy-induced senescent-like cancer cells, not stromal cells, are the dominant senescent-like and immunosuppressive population in cholangiocarcinoma, and their elimination restores antitumor immunity. GDF-15 is their dominant secreted effector and engages a non-canonical macrophage receptor, TGFBR2, identifying a cancer-cell-to-macrophage axis and a Sen-L-elimination strategy to restore chemosensitivity. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=170 SRC="FIGDIR/small/734341v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@7d3fd8org.highwire.dtl.DTLVardef@ea9efborg.highwire.dtl.DTLVardef@16ba16borg.highwire.dtl.DTLVardef@132b821_HPS_FORMAT_FIGEXP M_FIG Graphical abstract. Senescent-like CCA cells promote tumor immunosuppression through TAMs polarization by GDF-15 C_FIG

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Journal of Hepatology
21 papers in training set
Top 0.1%
10.0%
2
Cell Reports
1498 papers in training set
Top 4%
7.4%
3
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.4%
5.6%
4
eLife
5828 papers in training set
Top 20%
5.6%
5
Nature Communications
5641 papers in training set
Top 28%
5.3%
6
Gastroenterology
42 papers in training set
Top 0.2%
4.4%
7
JCI Insight
277 papers in training set
Top 2%
3.2%
8
Genome Medicine
183 papers in training set
Top 2%
2.7%
9
Cell Reports Medicine
153 papers in training set
Top 1%
2.7%
10
Cancer Research
130 papers in training set
Top 1%
2.5%
11
Clinical Cancer Research
64 papers in training set
Top 0.8%
2.5%
50% of probability mass above
12
Cellular and Molecular Gastroenterology and Hepatology
46 papers in training set
Top 0.4%
2.5%
13
Science Advances
1243 papers in training set
Top 14%
2.4%
14
Gut
40 papers in training set
Top 0.4%
2.4%
15
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 23%
2.2%
16
Nature Metabolism
69 papers in training set
Top 1.0%
1.9%
17
Journal of Clinical Investigation
179 papers in training set
Top 3%
1.8%
18
Cancer Cell
42 papers in training set
Top 0.7%
1.8%
19
Hepatology
22 papers in training set
Top 0.2%
1.5%
20
Communications Biology
993 papers in training set
Top 20%
1.2%
21
Aging Cell
165 papers in training set
Top 2%
1.2%
22
Gastro Hep Advances
11 papers in training set
Top 0.3%
1.1%
23
Communications Medicine
113 papers in training set
Top 4%
1.1%
24
Frontiers in Immunology
638 papers in training set
Top 8%
1.1%
25
Nature Genetics
286 papers in training set
Top 5%
0.9%
26
PLOS ONE
5266 papers in training set
Top 60%
0.9%
27
iScience
1154 papers in training set
Top 38%
0.6%
28
Scientific Reports
3612 papers in training set
Top 77%
0.6%
29
The EMBO Journal
309 papers in training set
Top 7%
0.6%
30
Nature
645 papers in training set
Top 11%
0.6%